共 146 条
[11]
Joseph N(2002)Novel V600E Hum Pathol 33 459-465
[12]
Steigen SE(2007) mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors Hepato-Gastroenterology 54 2285-2290
[13]
Eide TJ(2009)Diagnosis of gastrointestinal stromal tumors: a consensus approach J Clin Pathol 62 613-616
[14]
Wasag B(2011)Analysis of mutation and expression of c-kit and PDGFR-α gene in gastrointestinal stromal tumor Cancer Lett 312 43-54
[15]
Lasota J(2006)V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours Semin Diagn Pathol 23 70-83
[16]
Miettinen M(2003)Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST) J Clin Oncol 21 4342-4349
[17]
Dagher R(2008)Gastrointestinal stromal tumors: pathology and prognosis at different sites J Clin Oncol 26 626-632
[18]
Cohen M(2006)Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor Eur J Cancer 42 1093-1103
[19]
William G(2005)Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 Clin Cancer Res 11 4182-4190
[20]
Rothmann M(2006)KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours J Clin Oncol 24 4764-4774